La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Centene Crescita futura

Future criteri di controllo 1/6

Centene prevede che gli utili e i ricavi cresceranno rispettivamente di 7.7% e 5% all'anno. Si prevede che l'EPS crescerà di 12.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.5% in 3 anni.

Informazioni chiave

7.7%

Tasso di crescita degli utili

12.1%

Tasso di crescita dell'EPS

Healthcare crescita degli utili	19.4%
Tasso di crescita dei ricavi	5.0%
Rendimento futuro del capitale proprio	13.5%
Copertura analitica	Good
Ultimo aggiornamento	09 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Centene (NYSE:CNC) Seems To Use Debt Quite Sensibly

Aug 20

Centene Corporation: Strategic Market Position Amid Favorable Trends, Buy

Aug 20

Centene (NYSE:CNC) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 02

Centene appoints new leadership; Ken Fasola President of Centene, Dave Thomas CEO of Medicaid

Dec 14

An Intrinsic Calculation For Centene Corporation (NYSE:CNC) Suggests It's 50% Undervalued

Nov 11

Is Now The Time To Put Centene (NYSE:CNC) On Your Watchlist?

Oct 26

Centene Q3 2022 Earnings Preview

Oct 24

Centene: Future Growth Will Exceed Market Expectations

Oct 14

Centene: A Chaos Stock

Sep 28

Does Centene (NYSE:CNC) Have A Healthy Balance Sheet?

Sep 20

Centene falls 7%, most since April 2021, on surging volume

Sep 14

If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity

Jul 28

Centene Q2 2022 Earnings Preview

Jul 25

Centene Keeps Overdelivering - But Is Expensive

Jul 11

Is Centene (NYSE:CNC) Using Too Much Debt?

Jun 16

Centene: Solid Q122 Earnings For Health Insurer Helps Make Buy/Hold Case

Apr 28

Centene Has Overdelivered - It Is Time For A 'Hold'

Mar 24

Previsioni di crescita degli utili e dei ricavi

NYSE:CNC - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	166,298	3,538	4,103	5,291	11
12/31/2025	160,126	3,161	3,874	4,958	15
12/31/2024	156,347	3,110	2,006	3,037	11
6/30/2024	144,064	2,823	2,261	2,957	N/A
3/31/2024	142,800	2,735	2,603	3,328	N/A
12/31/2023	141,266	2,702	7,254	8,053	N/A
9/30/2023	139,354	2,444	5,451	6,260	N/A
6/30/2023	138,101	2,713	7,651	8,571	N/A
3/31/2023	136,941	1,483	8,392	9,379	N/A
12/31/2022	135,999	1,202	5,257	6,261	N/A
9/30/2022	132,756	2,014	7,493	8,512	N/A
6/30/2022	129,228	1,860	5,985	6,982	N/A
3/31/2022	124,181	1,497	4,348	5,313	N/A
12/31/2021	118,573	1,347	3,295	4,205	N/A
9/30/2021	114,130	736	5,643	6,511	N/A
6/30/2021	111,284	720	2,863	3,757	N/A
3/31/2021	108,158	2,461	4,907	5,786	N/A
12/31/2020	104,280	1,808	4,634	5,503	N/A
9/30/2020	95,764	2,029	1,008	1,871	N/A
6/30/2020	86,523	1,556	1,918	2,724	N/A
3/31/2020	78,105	845	-804	-73	N/A
12/31/2019	70,807	1,321	753	1,483	N/A
9/30/2019	68,385	1,353	784	1,500	N/A
6/30/2019	65,507	1,277	1,498	2,147	N/A
3/31/2019	61,028	1,082	71	704	N/A
12/31/2018	56,688	900	559	1,234	N/A
9/30/2018	52,618	889	1,708	2,318	N/A
6/30/2018	48,655	1,075	1,264	1,867	N/A
3/31/2018	47,201	1,029	N/A	2,087	N/A
12/31/2017	45,810	828	N/A	1,489	N/A
9/30/2017	44,870	853	N/A	2,631	N/A
6/30/2017	43,646	796	N/A	3,016	N/A
3/31/2017	42,468	713	N/A	2,903	N/A
12/31/2016	37,693	562	N/A	1,851	N/A
9/30/2016	32,839	416	N/A	460	N/A
6/30/2016	28,062	360	N/A	40	N/A
3/31/2016	22,948	277	N/A	809	N/A
12/31/2015	21,292	356	N/A	658	N/A
9/30/2015	19,854	350	N/A	827	N/A
6/30/2015	18,548	339	N/A	1,206	N/A
3/31/2015	17,102	298	N/A	1,016	N/A
12/31/2014	15,689	268	N/A	1,223	N/A
9/30/2014	14,134	210	N/A	1,023	N/A
6/30/2014	12,700	179	N/A	713	N/A
3/31/2014	11,475	172	N/A	591	N/A
12/31/2013	10,544	161	N/A	382	N/A
9/30/2013	9,427	209	N/A	183	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di CNC ( 7.7% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di CNC ( 7.7% all'anno) cresceranno più lentamente rispetto al mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di CNC cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di CNC ( 5% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CNC ( 5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di CNC sarà basso tra 3 anni ( 13.5 %).

Centene Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Centene Corporation Updates Earnings Guidance for the Year 2024

Centene Corporation Increases Premium and Service Revenues Guidance for the Fiscal Year 2024

Centene Corporation Provides Earnings Guidance for the Fiscal Year 2024

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Recent updates

Centene (NYSE:CNC) Seems To Use Debt Quite Sensibly

Centene Corporation: Strategic Market Position Amid Favorable Trends, Buy

Centene Corporation Announces the Election of Thomas R. Greco to Board of Directors

Centene (NYSE:CNC) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Centene Corporation to Report Q2, 2024 Results on Jul 26, 2024

Here's Why We Think Centene (NYSE:CNC) Is Well Worth Watching

A Piece Of The Puzzle Missing From Centene Corporation's (NYSE:CNC) Share Price

Returns At Centene (NYSE:CNC) Appear To Be Weighed Down

Centene Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Centene (NYSE:CNC) Is Using Debt Reasonably Well

Centene Corporation Still An Opportunity With An A-Grade Valuation

Centene Corporation, Annual General Meeting, May 14, 2024

If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity

Centene Corporation to Report Q1, 2024 Results on Apr 26, 2024

Market Still Lacking Some Conviction On Centene Corporation (NYSE:CNC)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Centene Corporation Increases Premium and Service Revenues Guidance for the Fiscal Year 2024

Centene Corporation Announces Appointment of Michael A. Carson as President and Chief Executive Officer of Its Medicare Business

Centene: Stay Defensive Amid Economic Uncertainty With This Low-Beta Bargain

Is Centene (NYSE:CNC) Using Too Much Debt?

Pure Health LLC completed the acquisition of Circle Health Group Limited from Centene Corporation (NYSE:CNC).

Centene Corporation to Report Fiscal Year 2023 Results on Feb 06, 2024

Centene Corporation Provides Earnings Guidance for the Fiscal Year 2024

Centene: Overlooked Healthcare Giant

Centene Corporation Announces the Appointment of Susan Smith as Chief Operating Officer, Effective January 1, 2024

Does Centene (NYSE:CNC) Deserve A Spot On Your Watchlist?

Centene: Solid Performance With Positive Outlook, But Limited Upside Potential

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Centene Corporation Names Wade Rakes as Chief Growth Officer

These 4 Measures Indicate That Centene (NYSE:CNC) Is Using Debt Reasonably Well

Decoding Centene: Why I Think It's Undervalued

Centene Corporation to Report Q3, 2023 Results on Oct 24, 2023

Pure Health LLC agreed to acquire Circle Health Group Limited from Centene Corporation (NYSE:CNC) for an enterprise value of approximately $1.2 billion.

If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Centene: Results Impress But Buyers Aren't Swarming Yet

Centene (NYSE:CNC) Has A Pretty Healthy Balance Sheet

Centene Corporation to Report Q2, 2023 Results on Jul 28, 2023

New Mountain Capital, L.L.C. acquired Apixio, Inc. from Centene Corporation.

Centene Corporation Appoints T. Susko as Its Senior Vice President and Chief Communications Officer

Centene Corporation Announces Resignation of James E. Murray as Chief Operating Officer

New Mountain Capital, L.L.C. agreed to acquire Apixio, Inc. from Centene Corporation (NYSE : CNC).

Centene to Divest AI Platform Apixio

Independent Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Centene (NYSE:CNC) Seems To Use Debt Quite Sensibly

CEO & Director recently bought US$1.9m worth of stock

Independent Director recently bought US$503k worth of stock

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Full year 2022 earnings: EPS misses analyst expectations

Centene Non-GAAP EPS of $0.86 beats by $0.02, revenue of $35.56B beats by $190M

With EPS Growth And More, Centene (NYSE:CNC) Makes An Interesting Case

Centene (NYSE:CNC) Seems To Use Debt Rather Sparingly

Centene: Once Again, With Quality, Now A 'Buy'

Centene Corporation to Report Fiscal Year 2022 Results on Feb 07, 2023

Centene Corporation Announces Management Changes

Centene appoints new leadership; Ken Fasola President of Centene, Dave Thomas CEO of Medicaid

Vivalto Santé SA completed the acquisition of Torrejon Salud, S.A. from Centene Corporation (NYSE:CNC).

Vivalto Santé SA completed the acquisition of Ribera Salud, S.A from Centene Corporation (NYSE:CNC).

Centene Corporation Appoints Monte Ford to Board of Directors

High number of new directors

An Intrinsic Calculation For Centene Corporation (NYSE:CNC) Suggests It's 50% Undervalued

Insider notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations